Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 13/20 | 0.72 |
| ▸ | CDK2 | P24941 | 10/20 | 0.72 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.72 |
| ▸ | PIM1 | P11309 | 8/20 | 0.72 |
| ▸ | PRKACA | P17612 | 8/20 | 0.72 |
| ▸ | GSK3B | P49841 | 8/20 | 0.72 |
| ▸ | HIPK2 | Q9H2X6 | 8/20 | 0.72 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.72 |
| ▸ | FLT3 | P36888 | 4/20 | 0.72 |
| ▸ | JAK3 | P52333 | 4/20 | 0.72 |
| ▸ | CDK9 | P50750 | 4/20 | 0.72 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.72 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.72 |
| ▸ | PAK4 | O96013 | 3/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.72 |
| ▸ | CLK2 | P49760 | 3/20 | 0.72 |
| ▸ | CDK7 | P50613 | 3/20 | 0.72 |
| ▸ | PRKX | P51817 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044049 | 0.84 | ROCK2 (1.00) | CDC7CDK2ROCK2PIM1PRKACA | |
| SCHEMBL1083529 | 0.84 | CDC7 (1.00) | CDC7CDK2ROCK2PIM1PRKACA | |
| SCHEMBL8939619 | 0.82 | CLK4 (1.00) | CDC7CDK2ROCK2PIM1PRKACA | |
| SCHEMBL1045577 | 0.81 | CDC7 (1.00) | CDC7CDK2ROCK2PIM1PRKACA | |
| SCHEMBL1666229 | 0.81 | CDC7 (0.63) | CDC7CDK2ROCK2PIM1PRKACA | |
| SCHEMBL1050119 | 0.80 | CDC7 (0.70) | CDC7CDK2ROCK2PIM1PRKACA | |
| SCHEMBL31006592 | 0.78 | DYRK1A (1.00) | GSK3BDYRK1ACDK9MAPK1CLK4 | |
| SCHEMBL29283884 | 0.78 | DYRK1A (1.00) | GSK3BDYRK1ACDK9MAPK1CLK4 | |
| SCHEMBL8940185 | 0.77 | CLK4 (0.84) | CDC7CDK2ROCK2PIM1PRKACA | |
| SCHEMBL29775980 | 0.77 | CDC7 (0.59) | CDC7CDK2ROCK2PIM1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CDC7 274/4885CDK2 23/4885ROCK2 241/4885 |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | CDC7 274/4885CDK2 23/4885ROCK2 241/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CDC7 274/4885CDK2 23/4885ROCK2 241/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | CDC7 864/4885CDK2 154/4885ROCK2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.